Last mentioned: Feb 27, 2026
Operational Launch
The new facilities are expected to come online and begin API production.
Operational Launch
The North Chicago facilities are expected to begin full-scale API production.
Operational Launch
New facilities expected to come online to support next-gen drug production.
Construction Start
Anticipated groundbreaking for the two new manufacturing plants.
Construction Start
Groundbreaking expected for the two new advanced manufacturing sites.
Construction Start
Anticipated ground-breaking for the two new advanced manufacturing sites.
Manufacturing Expansion
AbbVie announces $380 million investment for North Chicago API facilities.
Manufacturing Expansion
AbbVie announces $380M investment for North Chicago API facilities.
Manufacturing Expansion
AbbVie announces $380 million investment for North Chicago API facilities.
$100B Pledge
AbbVie commits to $100 billion in U.S. R&D and capital investments over the next decade.
$100B Pledge
AbbVie commits to $100 billion in U.S. R&D and manufacturing over the next decade.
$100B Pledge
AbbVie commits to $100 billion in U.S. R&D and capital investments over the next decade.
RBC Capital has launched coverage of pharmaceutical giant AbbVie with an Outperform rating, signaling confidence in the company's growth trajectory. The initiation suggests that market concerns regarding biosimilar competition for Humira are overstated as newer immunology assets gain significant market share.
AbbVie has announced a $380 million investment to expand its manufacturing capabilities in North Chicago, Illinois, marking the first major step in a decade-long $100 billion commitment to U.S. research and development. The move aligns with federal efforts to localize pharmaceutical supply chains and reduce drug prices through direct-to-patient initiatives like TrumpRx.
AbbVie has announced a $380 million investment to expand its North Chicago manufacturing campus, marking the first major step in a $100 billion decade-long commitment to U.S. R&D. The initiative aims to localize active pharmaceutical ingredient production while integrating with the Trump administration's 'TrumpRx' program to lower drug costs.
AbbVie has announced a $380 million investment to expand active pharmaceutical ingredient (API) manufacturing in North Chicago, marking the first major step in a $100 billion decade-long commitment to U.S. R&D and production. The move aligns with federal efforts to reshore critical drug supply chains and lower costs through direct-to-patient channels like TrumpRx.